Global Genomics Market Analysis and Forecast
Meticulous Research®, a leading global market intelligence firm, has released its most recent comprehensive report titled "Genomics Market by Technology (Sequencing, Microarray, PCR, Nucleic Acid Extraction), Application (Drug Discovery, Diagnostics, Research), End User (Pharmaceutical, Hospital, Academic), Offering (Instrument, Consumable, Software) - Global Forecast to 2031."
According to this new study, the global genomics market is expected to reach $70.52
billion by 2031, rising at a
strong CAGR of 11.1% between 2024 and 2031. This significant increase
reflects the rapid integration of genetics into mainstream healthcare,
pharmacological innovation, and scientific research.
·
Market Overview
& Growth Drivers
The growth of the
genomics market is driven by several critical factors:
·
Genetic
and chronic diseases are becoming more prevalent.
·
Increasing
incorporation of genomic data into clinical workflows
·
Surge in public
and private investments in genomics research
·
Decreasing costs
of sequencing technologies
·
Expanding use of
genomics in personalized medicine and targeted therapies
However,
challenges such as a lack of standardized approaches, concerns around data
privacy, and a shortage of skilled personnel pose limitations to market
expansion.
·
Segment
Insights
·
1. Offering
The genomics
market is segmented into instruments, consumables, software, and services.
In 2024, consumables are expected to dominate due to their recurring use
in genomic research and diagnostic processes, particularly in NGS workflows.
·
2. Technology
Key technologies
include sequencing (NGS and others), microarray, PCR, and nucleic acid
extraction & purification. Sequencing technologies are forecasted to
exhibit the highest CAGR during the forecast period, fueled by advancements in
scalability, speed, and accuracy.
·
3. Application
Applications span
drug discovery & development, diagnostics, life science research, and
others. Drug discovery & development is projected to grow
fastest, supported by the rising demand for effective therapies for chronic
diseases like cancer and diabetes.
·
4. End Users
The primary end
users are pharmaceutical & biotechnology companies, hospitals,
diagnostic labs, CROs, and academic institutes. Pharmaceutical and biotech
companies are set to hold the largest share in 2024, leveraging genomics for
biomarker discovery, personalized medicine, and advanced research initiatives.
·
Geographic
Review: U.S. Leading Innovation
In 2024, North
America, led by the U.S., is expected to dominate the global genomics market.
The region benefits from significant R&D spending, high adoption of
advanced healthcare technologies, strong academic-industrial collaborations,
and a dense concentration of global players like Illumina, Thermo Fisher
Scientific, and Bio-Rad.
Key innovation
hubs in the U.S. include Boston, Silicon Valley, and San Diego, where
investment in precision medicine and biotech continues to surge.
·
Competitive
Landscape & Key Players
The U.S. is home
to several major players in the genomics space, including:
·
Illumina, Inc.
·
Thermo Fisher
Scientific Inc.
·
Danaher
Corporation
·
Bio-Rad
Laboratories, Inc.
·
Agilent
Technologies, Inc.
·
Pacific
Biosciences of California, Inc.
·
Myriad Genetics,
Inc.
Other influential
players include QIAGEN (Netherlands), Oxford Nanopore (U.K.), and BGI Genomics
(China).
Strategic moves
such as M&A, product launches, and partnerships are common, as
exemplified by Bio-Rad’s acquisition of Curiosity Diagnostics to enhance
rapid PCR system development.
·
Strategic
Opportunities for Stakeholders
·
Investment in NGS
and software platforms for clinical
genomics
·
Expansion of
personalized medicine pipelines through
genomics-based biomarkers
·
Data
collaboration with academic and clinical
institutions for population genomics
·
Building
workforce capabilities in
bioinformatics and genomic analytics
·
Future Outlook
Looking ahead,
the genomics industry is poised to reshape healthcare through predictive
diagnostics, digital health integration, and AI-driven genomic data
interpretation. For C-suite decision-makers, the U.S. genomics market
offers a ripe landscape for strategic investments, collaborations, and
innovation acceleration.
Download the
Sample Report to explore the full
strategic insights and data forecasts:
🔗 Download
Sample Report
For
inquiries:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Comments
Post a Comment